Published in Clin Infect Dis on November 28, 2006
Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis (2009) 3.76
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99
Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS (2009) 2.89
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med (2008) 2.82
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull World Health Organ (2010) 2.72
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis (2011) 2.15
Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care. BMC Pediatr (2008) 1.96
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One (2011) 1.82
Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol (2009) 1.67
Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc (2012) 1.66
Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv (2010) 1.65
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med (2014) 1.51
Multiplexed quantification of nucleic acids with large dynamic range using multivolume digital RT-PCR on a rotational SlipChip tested with HIV and hepatitis C viral load. J Am Chem Soc (2011) 1.51
Viral load testing in resource-limited settings. Clin Infect Dis (2006) 1.47
The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS (2009) 1.37
Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc (2011) 1.36
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr (2010) 1.36
Theoretical design and analysis of multivolume digital assays with wide dynamic range validated experimentally with microfluidic digital PCR. Anal Chem (2011) 1.32
Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr (2011) 1.31
Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One (2010) 1.28
Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc (2009) 1.25
HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc (2012) 1.21
Efficient on-chip isolation of HIV subtypes. Lab Chip (2012) 1.17
Evaluation of clinical and immunological markers for predicting virological failure in a HIV/AIDS treatment cohort in Busia, Kenya. PLoS One (2012) 1.10
Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Sex Transm Infect (2007) 1.08
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther (2009) 1.08
Concentration and purification of human immunodeficiency virus type 1 virions by microfluidic separation of superparamagnetic nanoparticles. Anal Chem (2010) 1.06
Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. BMC Infect Dis (2012) 1.05
Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa. AIDS (2011) 1.05
Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients. PLoS One (2012) 1.05
Membrane-based, sedimentation-assisted plasma separator for point-of-care applications. Anal Chem (2013) 1.01
Magnitude and Predictors of Anti-Retroviral Treatment (ART) Failure in Private Health Facilities in Addis Ababa, Ethiopia. PLoS One (2015) 1.01
Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis. J Acquir Immune Defic Syndr (2009) 0.99
Mechanistic evaluation of the pros and cons of digital RT-LAMP for HIV-1 viral load quantification on a microfluidic device and improved efficiency via a two-step digital protocol. Anal Chem (2013) 0.99
Measures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals. J Clin Virol (2014) 0.98
Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis (2010) 0.98
Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC Infect Dis (2013) 0.98
Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med (2009) 0.98
Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol (2015) 0.94
Increased robustness of single-molecule counting with microfluidics, digital isothermal amplification, and a mobile phone versus real-time kinetic measurements. Anal Chem (2013) 0.94
Current practices in laboratory monitoring of HIV infection. Indian J Med Res (2011) 0.94
Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay. PLoS One (2009) 0.93
A Portable, Pressure Driven, Room Temperature Nucleic Acid Extraction and Storage System for Point of Care Molecular Diagnostics. Anal Methods (2013) 0.91
Viral load testing in a resource-limited setting: quality control is critical. J Int AIDS Soc (2011) 0.90
Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges. AIDS Rev (2013) 0.88
A paradigm shift to prevent HIV drug resistance. PLoS Med (2008) 0.88
Economic and epidemiological impact of early antiretroviral therapy initiation in India. J Int AIDS Soc (2015) 0.88
Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children. J Acquir Immune Defic Syndr (2013) 0.87
On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings. AIDS Care (2015) 0.87
The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. Trop Med Int Health (2012) 0.86
Reading Out Single-Molecule Digital RNA and DNA Isothermal Amplification in Nanoliter Volumes with Unmodified Camera Phones. ACS Nano (2016) 0.86
Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS One (2014) 0.84
Optimal Allocation of Gold Standard Testing under Constrained Availability: Application to Assessment of HIV Treatment Failure. J Am Stat Assoc (2013) 0.84
Limited utility of dried-blood- and plasma spot-based screening for antiretroviral treatment failure with Cobas Ampliprep/TaqMan HIV-1 version 2.0. J Clin Microbiol (2014) 0.83
Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique. J Acquir Immune Defic Syndr (2015) 0.83
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection in Seoul, South Korea. Scand J Infect Dis (2013) 0.82
Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. PLoS Med (2012) 0.82
Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. AIDS Res Hum Retroviruses (2012) 0.82
HIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City. AIDS Res Treat (2011) 0.80
Sample concentration and purification for point-of-care diagnostics. Conf Proc IEEE Eng Med Biol Soc (2012) 0.79
Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. Sci Rep (2015) 0.79
Simulation of pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection in Seoul, South Korea. J Acquir Immune Defic Syndr (2013) 0.78
Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health (2014) 0.78
Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire. J Int AIDS Soc (2010) 0.78
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr (2016) 0.78
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire. J Acquir Immune Defic Syndr (2014) 0.77
Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections. Emerg Microbes Infect (2012) 0.77
A Self-Reported Adherence Measure to Screen for Elevated HIV Viral Load in Pregnant and Postpartum Women on Antiretroviral Therapy. AIDS Behav (2016) 0.77
Short communication: prospective comparison of qualitative versus quantitative polymerase chain reaction for monitoring virologic treatment failure in HIV-infected patients. AIDS Res Hum Retroviruses (2014) 0.75
Cohort profile: improving treatment of HIV-infected Ethiopian children through better detection of treatment failure in southern Ethiopia. BMJ Open (2017) 0.75
A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort. AIDS Res Hum Retroviruses (2016) 0.75
Sensitivity and specificity of dried blood spots for HIV-1 viral load quantification: A laboratory assessment of 3 commercial assays. Medicine (Baltimore) (2016) 0.75
No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project. BMC Public Health (2016) 0.75
Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana. BMC Infect Dis (2016) 0.75
Impact of Viral Load Use on Treatment Switch in Perinatally HIV-Infected Children in Asia. AIDS Res Hum Retroviruses (2016) 0.75
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal. Afr J Prim Health Care Fam Med (2016) 0.75
Emerging and Neglected Infectious Diseases: Insights, Advances, and Challenges. Biomed Res Int (2017) 0.75
High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study. Medicine (Baltimore) (2017) 0.75
Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013. AIDS Care (2017) 0.75
Assessment of WHO criteria for identifying ART treatment failure in Vietnam from 2007 to 2011. PLoS One (2017) 0.75
Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution. J Acquir Immune Defic Syndr (2017) 0.75
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 11.72
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (2004) 11.18
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis (2007) 5.27
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 5.13
Technologies for global health. Lancet (2012) 5.05
25 years of the WHO essential medicines lists: progress and challenges. Lancet (2003) 4.95
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (2010) 4.41
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA (2003) 3.58
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis (2005) 3.57
Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS (2009) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. Bull World Health Organ (2005) 3.51
Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS (2012) 3.50
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ (2007) 3.41
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med (2013) 3.15
Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS (2004) 3.04
Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2012) 3.00
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis (2011) 2.98
Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr (2011) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis (2006) 2.93
A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis (2006) 2.92
Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health (2010) 2.92
A microfluidic device for practical label-free CD4(+) T cell counting of HIV-infected subjects. Lab Chip (2006) 2.89
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80
Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med (2006) 2.73
Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis (2006) 2.72
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature (2006) 2.61
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One (2010) 2.53
Responding to the human resource crisis: peer health workers, mobile phones, and HIV care in Rakai, Uganda. AIDS Patient Care STDS (2008) 2.48
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA (2008) 2.45
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.45
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis (2008) 2.35
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis (2005) 2.35
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc (2009) 2.31
The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med (2012) 2.29
Cognitive behavioral therapy and aerobic exercise for Gulf War veterans' illnesses: a randomized controlled trial. JAMA (2003) 2.26
WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. AIDS (2007) 2.26
Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics (2007) 2.24
Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis (2011) 2.21
Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis (2010) 2.21
They call it "patient selection" in Khayelitsha: the experience of Médecins Sans Frontières-South Africa in enrolling patients to receive antiretroviral treatment for HIV/AIDS. Camb Q Healthc Ethics (2006) 2.21
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS (2007) 2.19
Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev (2013) 2.17
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis (2010) 2.17
Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis (2003) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2010) 2.12
Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One (2011) 2.11
Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population. PLoS One (2009) 2.09
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
Impact of a mHealth intervention for peer health workers on AIDS care in rural Uganda: a mixed methods evaluation of a cluster-randomized trial. AIDS Behav (2011) 2.08
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med (2010) 2.05
Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? AIDS (2013) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Mortality, violence and lack of access to healthcare in the Democratic Republic of Congo. Disasters (2003) 2.04
Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A (2009) 2.03
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03